ONZETRA Xsail (sumatriptan intranasal) / Otsuka, OptiNose  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ONZETRA Xsail (sumatriptan intranasal) / Otsuka
NCT01462812: Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Checkmark TARGET & COMPASS
Jun 2016 - Jun 2016: TARGET & COMPASS
Checkmark AAN 2016
Apr 2016 - Apr 2016: AAN 2016
Checkmark AAN 2016
More
Completed
3
223
US
Sumatriptan, Placebo
Optinose US Inc.
Migraine Headache
06/12
06/12
COMPASS, NCT01667679: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Checkmark TARGET & COMPASS
Jun 2016 - Jun 2016: TARGET & COMPASS
Checkmark COMPASS
Jun 2016 - Jun 2016: COMPASS
Checkmark COMPASS
More
Completed
3
275
US
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Avanir Pharmaceuticals
Migraine, Headaches
03/14
06/14
NCT03338920: Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Terminated
3
159
US
sumatriptan nasal powder, AVP-825, ONZETRA® Xsail®, Placebo
Currax Pharmaceuticals
Acute Migraine With or Without Aura
04/22
04/22

Download Options